Despite an increase in transparency and collaboration in China, the safety of drugs and other products imported from the country remains a concern in the U.S. Read More
Salix Pharmaceuticals Ltd. said its two pivotal studies of budesonide foam in active to moderate ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS) hit the primary endpoints, with a statistically significant number of patients in the treatment arm achieving clinical remission vs. placebo. Read More
Over the past few years, a shift has occurred in how researchers think of neurodevelopmental disorders. Such disorders were once considered immutable once the faulty wiring that was presumed to be at their heart was put in place during development. Read More
Oncolytics Biotech Inc. followed up March's promising data from a Phase II trial testing Reolysin in squamous cell lung cancer with results from a Phase II study in metastatic melanoma, where the reovirus variant for Ras-mutant cancers, combined with carboplatin and paclitaxel, met its primary endpoint in the first stage. Read More
• Corgenix Medical Corp., of Denver, said it inked a collaboration agreement with Eli Lilly and Co., of Indianapolis, to develop diagnostic technology to support an undisclosed Lilly oncology pipeline program. Read More
• Agenus Inc., Lexington, Mass., started enrollment of a Phase II study with Prophage G-200 (heat shock protein peptide complex-96 or HSPPC-96) vaccine in combination with Avastin (bevacizumab, Genentech/Roche) for treatment of recurrent glioblastoma multiforme in adult patients. Read More
• Merck & Co. Inc., of Whitehouse Station, N.J., said it entered an accelerated share repurchase (ASR) agreement with Goldman, Sachs & Co. to repurchase $5 billion of common stock. Read More
• Upsher-Smith Laboratories Inc., of Maple Grove, Minn., completed a global Phase III trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults. Read More
